Oak Longevity vs Ro.co: Compounded Prices vs FDA-Approved Wegovy

Oak Longevity vs Ro.co compares two different telehealth approaches to GLP-1 weight-loss care. Early verdict: choose Oak Longevity if your priority is lowest compounded pricing and no subscription; choose Ro.co if you need an FDA-approved oral option and brand-level regulatory assurance.

Start Oak Longevity: view semaglutide from $133/mo

How these providers differ at a glance

This comparison focuses on the most distinctive supported differences: pricing model and starting cost, medication type and regulatory status, clinical access flow and testing requirements, and included services like shipping and coaching. Throughout we use only supplied facts and qualifiers.

Pricing model and upfront costs

Oak Longevity advertises flat, low compounded prices: semaglutide starting at $133/mo and tirzepatide starting at $199/mo, with one price covering all dosages and no subscriptions or membership fees. Oak bills monthly on a non-recurring basis and notes three-month prescriptions are billed upfront; no refunds are available after physician approval and once medication has shipped. Ro.co’s captured evidence emphasizes an entry price of “get started online for just $39,” and states ongoing branded medication pricing depends on the treatment plan and medication prescribed.

Compare Oak pricing and policies

Medication type and regulatory clarity

Oak Longevity sells compounded GLP-1 medications. The source explicitly states compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Ro.co is documented as offering the Wegovy pill, the first and only FDA-approved oral GLP-1 weight loss medication, and the source highlights that Ro is the only mainstream platform on the list with access to that oral FDA-approved option. This is the clearest regulatory difference: Oak provides compounded options; Ro.co provides an FDA-approved finished product.

See Ro.co’s Wegovy pill option

Access, clinical review, and practical limits

Oak uses an asynchronous licensed clinician review process with no video call required; patients complete an online questionnaire and a board-certified physician in the state reviews cases. Oak states patients with BMI below 20 don’t qualify for GLP-1 treatment and elsewhere notes not appropriate for BMI under 22 without comorbidities. Ro.co requires a licensed clinician to determine therapy is medically appropriate; pricing is disclosed before consultation. The captured Ro.co evidence does not detail video call requirements or shipping timelines.

Included services and operational differences

Oak includes free health coaching and free shipping with tracking as part of its offering and advertises same-day approval for qualifying patients. Ro.co’s captured content emphasizes regulatory assurance and that it does not offer compounded injectables as its primary differentiator; no captured evidence on shipping or coaching was available for Ro.co.

Quick final comparison

Oak Longevity vs Ro.co presents a trade-off: Oak emphasizes lower-cost compounded injectables with free coaching and shipping and a non-recurring monthly billing model; Ro.co emphasizes access to the FDA-approved Wegovy pill and starts with a $39 online entry point, with ongoing branded pricing that varies.

Conclusion: Choose based on priorities

Choose Oak Longevity if you are cost-conscious and want the lowest advertised compounded GLP-1 prices, no subscription or membership fees, free health coaching, free shipping, and an asynchronous clinician review process. Choose Ro.co if you prioritize an FDA-approved oral GLP-1 option (Wegovy pill), want the regulatory clarity of a finished medication, or are injection-averse; Ro.co lets you get started online for just $39 with pricing disclosed before consultation.

Start Ro.co: explore FDA-approved oral GLP-1

Start Oak Longevity: review compounded pricing and free coaching